公司披露中报，呋喹替尼海外销售持续增长。(市场销售口径，下同)FRUZAQLA25H1收入1.63亿美金，同比增长25%(固定汇率，下同)。海外渗透率持续提升。国内方面，爱优特(呋喹替尼)25H1收入0.43亿美金，同比-29%；苏泰达(索凡替尼)收入0.13亿美金，同比-50%；沃瑞沙(赛沃替尼)收入0.15亿美金，同比-41%。跟踪公司中报电话会，主要原因为暂时性竞争加剧所致，预计逐步缓解，已...
Source Link公司披露中报，呋喹替尼海外销售持续增长。(市场销售口径，下同)FRUZAQLA25H1收入1.63亿美金，同比增长25%(固定汇率，下同)。海外渗透率持续提升。国内方面，爱优特(呋喹替尼)25H1收入0.43亿美金，同比-29%；苏泰达(索凡替尼)收入0.13亿美金，同比-50%；沃瑞沙(赛沃替尼)收入0.15亿美金，同比-41%。跟踪公司中报电话会，主要原因为暂时性竞争加剧所致，预计逐步缓解，已...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.